HighMark Wealth Management’s Definium Therapeutics DFTX Stock Holding History

HighMark Wealth Management’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.89K	Hold	100	–	–	﹤0.01%	464
2025 Q4	$1.34K	Hold	100	–	–	﹤0.01%	500
2025 Q3	$1.18K	Hold	100	–	–	﹤0.01%	522
2025 Q2	$649	Hold	100	–	–	﹤0.01%	547
2025 Q1	$585	Hold	100	–	–	﹤0.01%	519
2024 Q4	$696	Buy	100 +22	+28%	+$151	﹤0.01%	513
2024 Q3	$444	Hold	78	–	–	﹤0.01%	549
2024 Q2	$562	Buy	78 +50	+179%	+$437	﹤0.01%	531
2024 Q1	$263	Hold	28	–	–	﹤0.01%	546
2023 Q4	$102	Hold	28	–	–	﹤0.01%	566
2023 Q3	$88	Sell	28 -1	-3%	-$4	﹤0.01%	558
2023 Q2	$104	Hold	29	–	–	﹤0.01%	551
2023 Q1	$92	Sell	29 -26	-47%	-$86	﹤0.01%	594
2022 Q4	$121	Sell	55 -59	-52%	-$164	﹤0.01%	525
2022 Q3	$0	Sell	114 -31	-21%	-$298	﹤0.01%	544
2022 Q2	$1K	Buy	145 +11	+8%	+$139	﹤0.01%	481
2022 Q1	$2K	Buy	+134	New	+$2.33K	﹤0.01%	449

Other funds holding DFTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HighMark Wealth Management's DFTX Position: Q1 2026 in Review

HighMark Wealth Management held its Definium Therapeutics (DFTX) position steady in Q1 2026 at 100 shares worth $1.89K. The position accounts for ﹤0.01% of the portfolio, ranked #464.

HighMark Wealth Management first reported a position in DFTX in Q1 2022 and has held it in 17 quarters since. The position peaked at $2K in Q1 2022. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

HighMark Wealth Management held 100 shares of Definium Therapeutics worth $1.89K as of Q1 2026.
HighMark Wealth Management left its Definium Therapeutics share count unchanged in Q1 2026.
Definium Therapeutics made up ﹤0.01% of HighMark Wealth Management's portfolio in Q1 2026, its #464 holding.
HighMark Wealth Management first reported a position in Definium Therapeutics in Q1 2022 and has held it in 17 quarters since.
HighMark Wealth Management's Definium Therapeutics position peaked at $2K in Q1 2022.
247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on HighMark Wealth Management's 13F filing for Q1 2026, filed 6 May 2026.